Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076688 | 0.88 | CYP11B2 (0.39) | CYP11B2CYP11B1MAOAGRM2AR | |
| SCHEMBL1076522 | 0.85 | CYP11B2 (0.44) | CYP11B2CYP11B1MAOAGRM2PDE10A | |
| SCHEMBL1039081 | 0.84 | ALDH1A1 (0.40) | CYP11B2CYP11B1MAOAL3MBTL1 | |
| SCHEMBL1078135 | 0.82 | CYP11B2 (0.40) | CYP11B2CYP11B1MAOAL3MBTL1 | |
| SCHEMBL1074996 | 0.82 | CYP11B2 (0.41) | CYP11B2CYP11B1MAOAFASNGRM2 | |
| SCHEMBL1036537 | 0.78 | ADORA1 (0.33) | CYP11B2ARUSP2HSD17B10L3MBTL1 | |
| SCHEMBL1077062 | 0.78 | ESR1 (0.38) | CYP11B2CYP11B1MAOAARUSP2 | |
| SCHEMBL1077582 | 0.75 | HSD17B10 (0.34) | CYP11B2ARUSP2HSD17B10L3MBTL1 | |
| SCHEMBL1036443 | 0.75 | MAOA (0.40) | MAOAHSD17B10L3MBTL1 | |
| SCHEMBL1077729 | 0.75 | L3MBTL1 (0.35) | CYP11B2ARUSP2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974776-B2 | Estrogen receptor beta agonists for use in treating mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2018-05-22 | — | — | US | claimed |
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2016-10-20 | — | — | US | claimed |
| EP-3076964-A1 | ESTROGEN RECEPTOR BETA AGONISTS FOR USE IN TREATING MESOTHELIOMA | Karo Pharma AB (SE) | 2016-10-12 | — | — | EP | claimed |
| WO-2016050945-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING ESTROGEN RECEPTOR-BETA AGONISTS WITH PLATINUM DRUGS OR PACLITAXEL FOR TREATING OVARIAN CANCER | KARO BIO AB (SE) | 2016-04-07 | — | — | WO | claimed |
| WO-2015082643-A1 | ESTROGEN RECEPTOR BETA AGONISTS FOR USE IN TREATING MESOTHELIOMA | KARO BIO AB (SE) | 2015-06-11 | — | — | WO | claimed |
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | claimed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | claimed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | claimed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | claimed |
| US-9974776-B2 | Estrogen receptor beta agonists for use in treating mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2016-10-20 | — | — | US | disclosed |
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | disclosed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | disclosed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | disclosed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | GPER1, ESR2, ESRRG | CYP11B2 1188/4885CYP11B1 929/4885MAOA 3803/4885 |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | ESR1, GPER1, ESRRA | CYP11B2 886/4885CYP11B1 591/4885MAOA 4402/4885 |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, GPER1, ESRRA | CYP11B2 840/4885CYP11B1 546/4885MAOA 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.